drugset
drugset / Trial / NCT01420042

Safety Study of NNZ-2566 in Healthy Subjects, Following Oral Administration

NCT01420042 ↗

Phase 1 Completed 24 enrolled Neuren Pharmaceuticals Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to obtain evidence of safety and determine the pharmacokinetics (PK) of NNZ-2566 in healthy volunteers, when administered orally.

Timeline

Start
2012-02
Primary completion
2012-08
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Trofinetide Peptide 6 mg/kg Oral
Subject Trofinetide Peptide 30 mg/kg Oral
Subject Trofinetide Peptide 100 mg/kg Oral

Indications

traumatic brain injury